© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
June 15, 2010
Novo Nordisk's Victoza (liraglutide), the first glucagon-like peptide-1 receptor agonist subcutaneous injection, received FDA approval for the treatment of type 2 diabetes mellitus.
May 11, 2010
Onglyza (saxagliptin) comarketed by Bristol-Myers Squibb and AstraZeneca, is FDA-approved to improve glycemic control for the treatment of type 2 diabetes.